January 2021

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification Bilthoven, the Netherlands, 21 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV) vaccine Eupolio™, developed by Intravacc and out-licensed to South Korean LG Chem in 2014. The…

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio Bilthoven, the Netherlands, 19 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than…

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics,  a technology leader in enabling safer and more effective therapeutics, today announced a strategic collaboration to develop novel vaccine programs…

Intravacc appoints three Supervisory Board members

Intravacc appoints three Supervisory Board members Bilthoven, the Netherlands, 4 January 2021 – Intravacc, a world leader in translational research and development of vaccines, announces the appointment of three members in its Supervisory Board. As of January 1, 2021, Intravacc has become an independent public shareholding company, the State of the Netherlands being the sole…